AK112 low dose + Chemotherapy + Olaparib + AK112 high dose
Phase 2Recruiting 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Platinum-sensitive Ovarian Cancer
Conditions
Platinum-sensitive Ovarian Cancer
Trial Timeline
Feb 17, 2025 → Jul 1, 2028
NCT ID
NCT06686030About AK112 low dose + Chemotherapy + Olaparib + AK112 high dose
AK112 low dose + Chemotherapy + Olaparib + AK112 high dose is a phase 2 stage product being developed by Akeso for Platinum-sensitive Ovarian Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06686030. Target conditions include Platinum-sensitive Ovarian Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06686030 | Phase 2 | Recruiting |
Competing Products
4 competing products in Platinum-sensitive Ovarian Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Farletuzumab + Placebo | Eisai | Phase 2 | 52 |
| OSE2101 + Pembrolizumab 25 MG/ML [Keytruda] | Merck | Phase 2 | 52 |
| Ipilimumab | Bristol Myers Squibb | Phase 2 | 51 |
| ZL-2306(nirapairb) + Placebos | Zai Lab | Phase 3 | 72 |